Kernal Biologics Announces $25M Series A Financing To Advance Its Mrna 2.0 Technology For Oncology
07/07/22, 7:00 AM
Location
Money raised
$25 million
Round Type
series a
Kernal Biologics, Inc. (Kernal Bio) — a development-stage mRNA-technology company developing cancer therapeutics designed to improve patients' survival rate and quality of life — today announced the completion of a $25 million Series A financing led by Hummingbird Ventures. Amgen Ventures, HBM Genomics and Civilization Ventures along with other VCs, family offices and high net worth individuals also participated in the round.